Notably, PTK6 emerged as a detrimental factor in Adrenocortical carcinoma (ACC), Pancreatic adenocarcinoma (PAAD), Mesothelioma (MESO), Acute Myeloid Leukemia (LAML), Kidney renal clear cell carcinoma (KIRC), and Skin Cutaneous Melanoma (SKCM) (Figure 1B). Here, PTK6 is linked to acute myeloid leukemia.